STADA Arzneimittel Aktiengesellschaft
STADA Arzneimittel Aktiengesellschaft, commonly known as STADA, is a prominent player in the global pharmaceutical industry, headquartered in Bad Vilbel, Germany. Founded in 1895, the company has established a strong presence in Europe and beyond, focusing on the development, manufacturing, and marketing of generic and over-the-counter (OTC) products. STADA's core offerings include a diverse range of pharmaceuticals, particularly in the fields of pain management, dermatology, and respiratory health. The company is recognised for its commitment to quality and innovation, which has positioned it as a trusted provider in the healthcare sector. With a robust portfolio and a strategic focus on expanding its market reach, STADA continues to achieve significant milestones, reinforcing its status as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does STADA Arzneimittel Aktiengesellschaft's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
STADA Arzneimittel Aktiengesellschaft's score of 28 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
STADA Arzneimittel Aktiengesellschaft's reported carbon emissions
In 2023, STADA Arzneimittel Aktiengesellschaft reported total carbon emissions of approximately 99,238,000 kg CO2e. This figure includes 42,696,000 kg CO2e from Scope 1 emissions and 56,542,000 kg CO2e from Scope 2 emissions. Notably, the company also disclosed Scope 3 emissions, which amounted to a significant 900,000,000 kg CO2e. Comparatively, in 2022, STADA's total emissions were about 109,954,000 kg CO2e, with Scope 1 and Scope 2 emissions at 42,433,000 kg CO2e and 67,521,000 kg CO2e, respectively. This indicates a reduction in total emissions from 2022 to 2023, showcasing the company's commitment to lowering its carbon footprint. STADA has committed to near-term climate targets, although specific reduction targets have not been detailed. The company is actively engaged in sustainability initiatives within the pharmaceuticals, biotechnology, and life sciences sector, reflecting its dedication to addressing climate change. Overall, STADA's emissions data and commitments highlight its ongoing efforts to manage and reduce its carbon emissions, aligning with industry standards for climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 38,202,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 93,417,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
STADA Arzneimittel Aktiengesellschaft is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
